In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured byHamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]
In a study published in 2011, using theMontgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]
In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]
^abcDubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression".Journal of Psychiatric Research.44 (6):356–363.doi:10.1016/j.jpsychires.2009.09.013.PMID19909980.
^abPangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder".Journal of Psychiatric Research.45 (6):748–755.doi:10.1016/j.jpsychires.2011.03.014.PMID21511276.
